GBT Announces Participation at the Wedbush PacGrow Healthcare Conference
Global Blood Therapeutics (GBT) announced its participation in a virtual fireside chat at the Wedbush PacGrow Healthcare Conference on August 11, 2021, at 2:20 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Global Blood Therapeutics (GBT) announced its participation in a virtual fireside chat at the Wedbush PacGrow Healthcare Conference on August 11, 2021, at 2:20 p.m. ET. The event will be streamed live on GBT’s website, with an archived replay available for a month.
GBT focuses on developing treatments for sickle cell disease (SCD), including the FDA-approved Oxbryta® and other promising pipeline programs like inclacumab and GBT021601.
Positive
- Participation in a noteworthy healthcare conference enhances visibility.
- Oxbryta® represents a significant advancement in SCD treatment.
- Pipeline includes promising drugs like inclacumab and GBT021601.
Negative
- None.
Details
News Market Reaction – GBT
The recorded move for GBT in the trading session of this news was +19.97%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the Wedbush PacGrow Healthcare Conference on Wednesday, August 11, 2021, at 2:20 p.m. ET.
The fireside chat will be webcast live from GBT’s website at www.gbt.com in the Investors section. A replay of the webcast will be archived and available for one month following the event.
About Global Blood Therapeutics
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in Phase 3 development to address pain crises associated with the disease, and GBT021601 (GBT601), the company’s next-generation hemoglobin S polymerization inhibitor. In addition, GBT’s drug discovery teams are working on new targets to develop the next wave of potential treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.
Contact:
Steven Immergut (media)
650-410-3258
simmergut@gbt.com
Courtney Roberts (investors)
650-351-7881
croberts@gbt.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.